Literature DB >> 16688819

Pathogenesis of primary biliary cirrhosis: a unifying model.

Elias Kouroumalis, George Notas.   

Abstract

Primary biliary cirrhosis (PBC) is a disease of unknown etiology leading to progressive destruction of small intrahepatic bile ducts and eventually to liver cirrhosis and failure. It is characterised by female predominance and serum auto-antibodies to mitochondrial antigens targeting the E2 components of the 2-oxoacid dehydrogenase complex. Although they are associated with disease pathogenesis, no concrete evidence has been presented so far. Epidemiological data indicate that a geographical clustering of cases and possible environmental factors are implicated in pathogenesis. A number of genetic factors play a role in determining disease susceptibility or progression, although no definitive conclusion has been reached so far. A key factor to immune pathogenesis is considered to be the breakdown of immune tolerance, either through molecular mimicry or through the so called determinant density model. In this review, the available data regarding the pathogenesis of primary biliary cirrhosis are described and discussed. A new unifying hypothesis based on early endothelin overproduction in primary biliary cirrhosis (PBC) is presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688819      PMCID: PMC4088064          DOI: 10.3748/wjg.v12.i15.2320

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  96 in total

1.  T-cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis.

Authors:  D E Jones; J M Palmer; O F James; S J Yeaman; M F Bassendine; A G Diamond
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

2.  Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids.

Authors:  R J Sokol; B M Winklhofer-Roob; M W Devereaux; J M McKim
Journal:  Gastroenterology       Date:  1995-10       Impact factor: 22.682

3.  Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis: applications of a semiautomated assay.

Authors:  K L Teoh; M J Rowley; H Zafirakis; E R Dickson; R H Wiesner; M E Gershwin; I R MacKay
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

4.  Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression.

Authors:  K Tsuneyama; J Van de Water; P S Leung; S Cha; Y Nakanuma; M Kaplan; R De Lellis; R Coppel; A Ansari; M E Gershwin
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

5.  Quantitative analysis of macrophages and perisinusoidal cells in primary biliary cirrhosis.

Authors:  J Mathew; J E Hines; K Toole; S J Johnson; O F James; A D Burt
Journal:  Histopathology       Date:  1994-07       Impact factor: 5.087

6.  Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis differ for mammalian, yeast and bacterial enzymes: implications for molecular mimicry.

Authors:  K L Teoh; I R Mackay; M J Rowley; S P Fussey
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

7.  Primary biliary cirrhosis. High proportions of B cells in blood and liver tissue produce anti-mitochondrial antibodies of several Ig classes.

Authors:  A Björkland; L Lööf; I Mendel-Hartvig; T H Tötterman
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

8.  Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis?

Authors:  P Butler; J Hamilton-Miller; H Baum; A K Burroughs
Journal:  Biochem Mol Biol Int       Date:  1995-03

9.  Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis.

Authors:  J Van de Water; A Ansari; T Prindiville; R L Coppel; N Ricalton; B L Kotzin; S Liu; T E Roche; S M Krams; S Munoz; M E Gershwin
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

10.  HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases.

Authors:  S Shimoda; M Nakamura; H Ishibashi; K Hayashida; Y Niho
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis.

Authors:  Ourania Sfakianaki; Maria Tzardi; Argyro Voumvouraki; Aikaterini Afgoustaki; Meri Koulentaki; Elias Kouroumalis
Journal:  World J Hepatol       Date:  2013-10-27

Review 3.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

4.  Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients.

Authors:  Ourania Sfakianaki; Meri Koulentaki; Maria Tzardi; Elena Tsangaridou; Panayotis A Theodoropoulos; Elias Castanas; Elias A Kouroumalis
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

5.  CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.

Authors:  P Manousou; G Kolios; I Drygiannakis; M Koulentaki; K Pyrovolaki; A Voumvouraki; G Notas; L Bourikas; H A Papadaki; E Kouroumalis
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 6.  Rodent models of cholestatic liver disease: A practical guide for translational research.

Authors:  Eva Gijbels; Alanah Pieters; Kevin De Muynck; Mathieu Vinken; Lindsey Devisscher
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.